| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunoassay | 13 | 2024 | 91 | 2.900 |
Why?
|
| Pharmacogenetics | 12 | 2023 | 437 | 1.910 |
Why?
|
| Clinical Chemistry Tests | 4 | 2019 | 11 | 1.730 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 311 | 1.640 |
Why?
|
| Hemolysis | 4 | 2023 | 64 | 1.320 |
Why?
|
| Tacrolimus | 2 | 2024 | 369 | 1.230 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2024 | 104 | 1.220 |
Why?
|
| Precision Medicine | 5 | 2023 | 409 | 1.140 |
Why?
|
| Immunoglobulin M | 4 | 2021 | 163 | 1.130 |
Why?
|
| Pre-Eclampsia | 5 | 2022 | 255 | 1.000 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 4 | 2022 | 94 | 0.920 |
Why?
|
| Automation, Laboratory | 2 | 2020 | 12 | 0.880 |
Why?
|
| Peptide Fragments | 6 | 2011 | 462 | 0.870 |
Why?
|
| Vanadates | 1 | 2023 | 32 | 0.850 |
Why?
|
| Biotin | 1 | 2023 | 45 | 0.840 |
Why?
|
| Placenta Growth Factor | 4 | 2022 | 70 | 0.820 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2011 | 51 | 0.810 |
Why?
|
| Drug Monitoring | 2 | 2024 | 118 | 0.790 |
Why?
|
| Thyroid Function Tests | 1 | 2022 | 120 | 0.780 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 44 | 0.780 |
Why?
|
| Prostate-Specific Antigen | 1 | 2024 | 337 | 0.770 |
Why?
|
| Communicable Diseases, Imported | 1 | 2021 | 1 | 0.750 |
Why?
|
| Humans | 79 | 2024 | 89567 | 0.750 |
Why?
|
| Biomarkers | 10 | 2023 | 1768 | 0.740 |
Why?
|
| Serologic Tests | 1 | 2020 | 43 | 0.720 |
Why?
|
| Hyperkalemia | 2 | 2012 | 13 | 0.720 |
Why?
|
| Betacoronavirus | 2 | 2020 | 262 | 0.720 |
Why?
|
| Blood Specimen Collection | 2 | 2012 | 27 | 0.720 |
Why?
|
| Patient Safety | 1 | 2023 | 218 | 0.700 |
Why?
|
| Triiodothyronine | 1 | 2022 | 345 | 0.700 |
Why?
|
| Endothelial Growth Factors | 10 | 1996 | 55 | 0.660 |
Why?
|
| Lymphokines | 10 | 1996 | 75 | 0.660 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2019 | 45 | 0.620 |
Why?
|
| Parathyroidectomy | 1 | 2019 | 80 | 0.620 |
Why?
|
| Vitamin B 12 | 1 | 2018 | 24 | 0.610 |
Why?
|
| Smith-Lemli-Opitz Syndrome | 1 | 2018 | 2 | 0.610 |
Why?
|
| Parathyroid Hormone | 1 | 2019 | 220 | 0.590 |
Why?
|
| Adalimumab | 1 | 2018 | 87 | 0.580 |
Why?
|
| Testosterone | 2 | 2017 | 272 | 0.570 |
Why?
|
| Cholesterol | 2 | 2024 | 360 | 0.570 |
Why?
|
| Hypogonadism | 1 | 2017 | 40 | 0.570 |
Why?
|
| Pharmacogenomic Testing | 4 | 2022 | 95 | 0.550 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 2011 | 44 | 0.540 |
Why?
|
| Proteomics | 1 | 2018 | 231 | 0.540 |
Why?
|
| Chromatography, Liquid | 3 | 2024 | 106 | 0.530 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 202 | 0.530 |
Why?
|
| Cytochrome P-450 CYP2D6 | 5 | 2022 | 52 | 0.520 |
Why?
|
| Immunoglobulin G | 4 | 2021 | 469 | 0.520 |
Why?
|
| Chorionic Gonadotropin | 2 | 2014 | 72 | 0.510 |
Why?
|
| Sensitivity and Specificity | 6 | 2022 | 2015 | 0.500 |
Why?
|
| Fibromyalgia | 1 | 2015 | 14 | 0.500 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 976 | 0.470 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2014 | 39 | 0.470 |
Why?
|
| Analgesics | 1 | 2015 | 119 | 0.460 |
Why?
|
| Genotype | 7 | 2022 | 1853 | 0.450 |
Why?
|
| Myocardial Ischemia | 2 | 2005 | 162 | 0.440 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 156 | 0.430 |
Why?
|
| Chronic Pain | 1 | 2015 | 162 | 0.410 |
Why?
|
| Reagent Kits, Diagnostic | 4 | 2020 | 38 | 0.410 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 1732 | 0.410 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 2763 | 0.410 |
Why?
|
| Troponin I | 3 | 2003 | 26 | 0.390 |
Why?
|
| Potassium | 1 | 2012 | 258 | 0.370 |
Why?
|
| Nerve Tissue Proteins | 2 | 2004 | 511 | 0.370 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 160 | 0.370 |
Why?
|
| Genotyping Techniques | 1 | 2011 | 69 | 0.360 |
Why?
|
| Artifacts | 1 | 2012 | 246 | 0.360 |
Why?
|
| Legislation, Medical | 1 | 2010 | 9 | 0.360 |
Why?
|
| Warfarin | 2 | 2019 | 104 | 0.350 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 425 | 0.340 |
Why?
|
| Anticoagulants | 3 | 2019 | 428 | 0.340 |
Why?
|
| Antibodies, Heterophile | 2 | 2000 | 20 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2021 | 2411 | 0.340 |
Why?
|
| Pregnancy | 8 | 2022 | 3035 | 0.310 |
Why?
|
| Oxycodone | 2 | 2022 | 35 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 1353 | 0.300 |
Why?
|
| Female | 24 | 2022 | 46371 | 0.290 |
Why?
|
| False Positive Reactions | 4 | 2020 | 223 | 0.290 |
Why?
|
| Limit of Detection | 2 | 2018 | 20 | 0.270 |
Why?
|
| Bilirubin | 2 | 2023 | 131 | 0.260 |
Why?
|
| Rifampin | 1 | 2006 | 23 | 0.260 |
Why?
|
| Protein Precursors | 2 | 2011 | 140 | 0.250 |
Why?
|
| Exercise | 2 | 2005 | 326 | 0.250 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 201 | 0.240 |
Why?
|
| Transistors, Electronic | 1 | 2024 | 4 | 0.240 |
Why?
|
| Paper | 1 | 2024 | 12 | 0.240 |
Why?
|
| Biosensing Techniques | 1 | 2024 | 73 | 0.220 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2023 | 24 | 0.220 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2023 | 70 | 0.210 |
Why?
|
| Infant, Newborn | 5 | 2022 | 2487 | 0.210 |
Why?
|
| Cardiolipins | 1 | 2002 | 17 | 0.210 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 1727 | 0.210 |
Why?
|
| Male | 17 | 2024 | 42464 | 0.210 |
Why?
|
| Erythrocyte Transfusion | 2 | 2013 | 72 | 0.210 |
Why?
|
| Bias | 1 | 2023 | 134 | 0.200 |
Why?
|
| Neonatal Sepsis | 1 | 2022 | 5 | 0.200 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2005 | 331 | 0.200 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.200 |
Why?
|
| Chorioamnionitis | 1 | 2022 | 21 | 0.200 |
Why?
|
| Erythrocytes | 2 | 2013 | 254 | 0.200 |
Why?
|
| Pain Management | 2 | 2021 | 139 | 0.190 |
Why?
|
| Perioperative Care | 2 | 2022 | 168 | 0.190 |
Why?
|
| Travel Medicine | 1 | 2021 | 1 | 0.190 |
Why?
|
| Autoantibodies | 1 | 2002 | 268 | 0.190 |
Why?
|
| Cross Reactions | 1 | 2021 | 109 | 0.180 |
Why?
|
| Adult | 18 | 2022 | 26684 | 0.180 |
Why?
|
| Bacteremia | 1 | 2022 | 102 | 0.180 |
Why?
|
| Liver | 1 | 2006 | 1208 | 0.180 |
Why?
|
| Fetal Growth Retardation | 1 | 2021 | 68 | 0.180 |
Why?
|
| Jaundice | 1 | 2020 | 14 | 0.180 |
Why?
|
| Blood Proteins | 1 | 2001 | 149 | 0.180 |
Why?
|
| Equipment Design | 2 | 2021 | 420 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 76 | 0.180 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 23 | 0.180 |
Why?
|
| Thyroid Gland | 1 | 2022 | 280 | 0.180 |
Why?
|
| Hyperglycemia | 2 | 2001 | 172 | 0.180 |
Why?
|
| Hepatitis B Antibodies | 1 | 2020 | 16 | 0.170 |
Why?
|
| Middle Aged | 14 | 2021 | 25996 | 0.170 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 72 | 0.170 |
Why?
|
| Blood Chemical Analysis | 1 | 2000 | 41 | 0.170 |
Why?
|
| Genomics | 2 | 2019 | 774 | 0.170 |
Why?
|
| Pharmacogenomic Variants | 1 | 2020 | 41 | 0.170 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 92 | 0.170 |
Why?
|
| Platelet Function Tests | 1 | 2019 | 11 | 0.170 |
Why?
|
| Glycoproteins | 1 | 2001 | 234 | 0.170 |
Why?
|
| Mixed Function Oxygenases | 2 | 2010 | 69 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 419 | 0.170 |
Why?
|
| Inpatients | 1 | 2022 | 311 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factors | 10 | 1996 | 56 | 0.170 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2019 | 30 | 0.160 |
Why?
|
| Peripartum Period | 1 | 2019 | 30 | 0.160 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 316 | 0.160 |
Why?
|
| Case-Control Studies | 5 | 2022 | 1862 | 0.160 |
Why?
|
| Intraoperative Period | 1 | 2019 | 91 | 0.160 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 58 | 0.160 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 168 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 102 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2020 | 140 | 0.160 |
Why?
|
| Blood Pressure | 3 | 2019 | 902 | 0.150 |
Why?
|
| Serotonin | 1 | 2019 | 221 | 0.150 |
Why?
|
| Dehydrocholesterols | 1 | 2018 | 2 | 0.150 |
Why?
|
| Biological Availability | 1 | 2018 | 91 | 0.150 |
Why?
|
| Sepsis | 1 | 2022 | 326 | 0.150 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2019 | 315 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 10 | 1996 | 405 | 0.140 |
Why?
|
| Anesthesiology | 1 | 2019 | 157 | 0.140 |
Why?
|
| Prognosis | 4 | 2019 | 3783 | 0.140 |
Why?
|
| Administration, Cutaneous | 2 | 2015 | 59 | 0.140 |
Why?
|
| Vitamin D | 1 | 2019 | 269 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 450 | 0.140 |
Why?
|
| Myocardium | 1 | 2000 | 572 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2023 | 9112 | 0.140 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 1996 | 5 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2018 | 870 | 0.130 |
Why?
|
| Critical Care | 1 | 2019 | 383 | 0.130 |
Why?
|
| Prospective Studies | 6 | 2023 | 4309 | 0.130 |
Why?
|
| Fluoroimmunoassay | 2 | 1994 | 2 | 0.130 |
Why?
|
| Diabetic Retinopathy | 2 | 1994 | 91 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 250 | 0.130 |
Why?
|
| Child | 3 | 2023 | 7214 | 0.130 |
Why?
|
| Hypertension | 3 | 2018 | 745 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2001 | 565 | 0.130 |
Why?
|
| Heart Failure | 1 | 2005 | 1191 | 0.130 |
Why?
|
| Myalgia | 1 | 2015 | 7 | 0.130 |
Why?
|
| Libido | 1 | 2015 | 9 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1540 | 0.130 |
Why?
|
| Health Promotion | 1 | 2017 | 165 | 0.130 |
Why?
|
| Gels | 1 | 2015 | 49 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 305 | 0.120 |
Why?
|
| Blood Glucose | 3 | 2017 | 837 | 0.120 |
Why?
|
| Quality Control | 2 | 2012 | 117 | 0.120 |
Why?
|
| Vitreous Body | 1 | 1994 | 54 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 699 | 0.120 |
Why?
|
| Cytochrome P-450 CYP2C19 | 2 | 2011 | 8 | 0.120 |
Why?
|
| Fatigue | 1 | 2015 | 172 | 0.120 |
Why?
|
| Calibration | 1 | 2014 | 103 | 0.110 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 194 | 0.110 |
Why?
|
| Time Factors | 5 | 2012 | 5333 | 0.110 |
Why?
|
| Blood Preservation | 1 | 2013 | 10 | 0.110 |
Why?
|
| Hemoglobin, Sickle | 1 | 2013 | 19 | 0.110 |
Why?
|
| Hyperammonemia | 1 | 2013 | 13 | 0.110 |
Why?
|
| Vitamin K Epoxide Reductases | 2 | 2010 | 16 | 0.110 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2010 | 20 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1605 | 0.100 |
Why?
|
| Centrifugation | 1 | 2012 | 24 | 0.100 |
Why?
|
| Phlebotomy | 1 | 2012 | 22 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2001 | 1180 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 950 | 0.100 |
Why?
|
| Chest Pain | 1 | 2011 | 42 | 0.090 |
Why?
|
| Acute Coronary Syndrome | 1 | 2011 | 30 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 111 | 0.090 |
Why?
|
| Smoking | 2 | 2006 | 625 | 0.090 |
Why?
|
| Anemia, Sickle Cell | 1 | 2013 | 144 | 0.090 |
Why?
|
| Alleles | 2 | 2011 | 1136 | 0.090 |
Why?
|
| Drug Industry | 1 | 2011 | 54 | 0.090 |
Why?
|
| Drug Therapy | 1 | 2010 | 69 | 0.090 |
Why?
|
| Insulin | 2 | 2006 | 1148 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2010 | 476 | 0.080 |
Why?
|
| Cell Line | 2 | 2011 | 2494 | 0.080 |
Why?
|
| Glucuronosyltransferase | 1 | 2010 | 186 | 0.080 |
Why?
|
| Pain | 2 | 2022 | 399 | 0.080 |
Why?
|
| Vancomycin | 1 | 1989 | 73 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 92 | 0.080 |
Why?
|
| Troponin T | 2 | 2011 | 39 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 135 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2008 | 223 | 0.080 |
Why?
|
| Neoplasms | 2 | 2021 | 3053 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 885 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2641 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 524 | 0.070 |
Why?
|
| Nanotechnology | 1 | 2007 | 68 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2007 | 205 | 0.070 |
Why?
|
| Aged | 7 | 2021 | 19144 | 0.070 |
Why?
|
| Gene Duplication | 1 | 2007 | 128 | 0.070 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2006 | 42 | 0.070 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2006 | 42 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1131 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2006 | 79 | 0.060 |
Why?
|
| Narcotics | 1 | 2006 | 71 | 0.060 |
Why?
|
| Hydrocortisone | 2 | 2004 | 301 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 743 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2006 | 292 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 606 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 164 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2019 | 2878 | 0.060 |
Why?
|
| Algorithms | 1 | 2013 | 1896 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 693 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 222 | 0.060 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 54 | 0.060 |
Why?
|
| Edetic Acid | 1 | 2003 | 42 | 0.060 |
Why?
|
| Exercise Test | 1 | 2004 | 166 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2005 | 590 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2022 | 2304 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2023 | 22 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 351 | 0.050 |
Why?
|
| Kinetics | 2 | 2024 | 1534 | 0.050 |
Why?
|
| Ischemia | 1 | 2005 | 252 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 9299 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2023 | 75 | 0.050 |
Why?
|
| Pharmacists | 1 | 2022 | 33 | 0.050 |
Why?
|
| Nicotine | 1 | 2004 | 199 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2015 | 8209 | 0.050 |
Why?
|
| Omeprazole | 1 | 2022 | 11 | 0.050 |
Why?
|
| Succinylcholine | 1 | 2022 | 14 | 0.050 |
Why?
|
| Hydralazine | 1 | 2022 | 19 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 407 | 0.050 |
Why?
|
| United States | 2 | 2019 | 7041 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2002 | 64 | 0.050 |
Why?
|
| ROC Curve | 1 | 2004 | 777 | 0.050 |
Why?
|
| Young Adult | 3 | 2021 | 6362 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6766 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 373 | 0.050 |
Why?
|
| Dibenzothiazepines | 1 | 2001 | 4 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2002 | 153 | 0.050 |
Why?
|
| Risperidone | 1 | 2001 | 23 | 0.050 |
Why?
|
| Risk Factors | 3 | 2022 | 5523 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2003 | 298 | 0.050 |
Why?
|
| Long QT Syndrome | 1 | 2001 | 36 | 0.050 |
Why?
|
| Phenotype | 1 | 2007 | 2447 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2002 | 236 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 270 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2001 | 131 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2002 | 357 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2019 | 146 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2002 | 345 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2023 | 455 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 141 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 149 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 145 | 0.040 |
Why?
|
| Aortic Aneurysm | 1 | 1998 | 80 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 488 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 280 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1076 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 253 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 258 | 0.030 |
Why?
|
| Follicular Fluid | 1 | 1996 | 10 | 0.030 |
Why?
|
| Ovulation Induction | 1 | 1996 | 31 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 794 | 0.030 |
Why?
|
| Ascitic Fluid | 1 | 1996 | 38 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 182 | 0.030 |
Why?
|
| Semen | 1 | 1995 | 13 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3658 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 834 | 0.030 |
Why?
|
| Mitogens | 1 | 1995 | 62 | 0.030 |
Why?
|
| Seminal Vesicles | 1 | 1995 | 39 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2002 | 158 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1491 | 0.030 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1995 | 18 | 0.030 |
Why?
|
| Fetal Blood | 1 | 1995 | 93 | 0.030 |
Why?
|
| Birth Weight | 1 | 1995 | 148 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1996 | 391 | 0.030 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1995 | 109 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1887 | 0.030 |
Why?
|
| Receptors, Growth Factor | 1 | 1994 | 52 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 3174 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 652 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2006 | 387 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 775 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 1430 | 0.030 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2013 | 3 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 1996 | 354 | 0.030 |
Why?
|
| Hematocrit | 1 | 2013 | 68 | 0.030 |
Why?
|
| Ammonia | 1 | 2013 | 39 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1994 | 160 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1850 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 432 | 0.030 |
Why?
|
| Automation | 1 | 2013 | 111 | 0.030 |
Why?
|
| Microcirculation | 1 | 1992 | 104 | 0.030 |
Why?
|
| Fibrin | 1 | 1992 | 86 | 0.030 |
Why?
|
| Europium | 1 | 1992 | 2 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 1992 | 172 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 453 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1992 | 130 | 0.020 |
Why?
|
| Prostate | 1 | 1995 | 402 | 0.020 |
Why?
|
| Animals | 3 | 2005 | 27476 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2011 | 68 | 0.020 |
Why?
|
| Melanoma | 1 | 1996 | 467 | 0.020 |
Why?
|
| Greece | 1 | 2011 | 19 | 0.020 |
Why?
|
| Psoriasis | 1 | 1994 | 245 | 0.020 |
Why?
|
| Albumins | 1 | 2011 | 129 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1994 | 3024 | 0.020 |
Why?
|
| Pathology, Molecular | 1 | 2010 | 34 | 0.020 |
Why?
|
| Obesity | 1 | 2017 | 971 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 1995 | 1723 | 0.020 |
Why?
|
| Autoanalysis | 1 | 1989 | 6 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1989 | 39 | 0.020 |
Why?
|
| Heart Arrest, Induced | 1 | 1989 | 29 | 0.020 |
Why?
|
| Creatine | 1 | 1989 | 25 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1989 | 303 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2004 | 1708 | 0.020 |
Why?
|
| Hypothermia, Induced | 1 | 1989 | 82 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1992 | 2063 | 0.020 |
Why?
|
| Digoxin | 1 | 1987 | 21 | 0.020 |
Why?
|
| Absorption | 1 | 2006 | 25 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2006 | 39 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 121 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2006 | 192 | 0.020 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2006 | 56 | 0.020 |
Why?
|
| Mass Screening | 1 | 1990 | 644 | 0.020 |
Why?
|
| Genome, Human | 1 | 2010 | 791 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2006 | 336 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1989 | 1928 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 2 | 1995 | 50 | 0.020 |
Why?
|
| DNA | 1 | 2010 | 1309 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2006 | 353 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 227 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 661 | 0.010 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2002 | 17 | 0.010 |
Why?
|
| Etomidate | 1 | 2002 | 11 | 0.010 |
Why?
|
| Quetiapine Fumarate | 1 | 2001 | 4 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 2002 | 102 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2002 | 155 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2004 | 255 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2002 | 260 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 375 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1995 | 2884 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1995 | 2021 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2002 | 731 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 1995 | 1982 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1996 | 67 | 0.010 |
Why?
|
| Erythema Multiforme | 1 | 1995 | 4 | 0.010 |
Why?
|
| Dermatitis Herpetiformis | 1 | 1995 | 9 | 0.010 |
Why?
|
| Pemphigoid, Bullous | 1 | 1995 | 12 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1996 | 259 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1995 | 117 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1995 | 103 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 313 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1995 | 136 | 0.010 |
Why?
|
| Keratinocytes | 1 | 1995 | 146 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 1994 | 67 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 692 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 1048 | 0.010 |
Why?
|
| Transfection | 1 | 1996 | 909 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1996 | 816 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 1008 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1992 | 53 | 0.010 |
Why?
|
| Binding Sites | 1 | 1995 | 1120 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1992 | 91 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 1992 | 132 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2002 | 2296 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1996 | 1064 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 1798 | 0.010 |
Why?
|
| Gene Expression | 1 | 1995 | 1309 | 0.010 |
Why?
|
| Singapore | 1 | 1990 | 15 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 2329 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 1990 | 87 | 0.010 |
Why?
|
| Myocardial Revascularization | 1 | 1989 | 30 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1989 | 113 | 0.010 |
Why?
|
| Heart Valve Prosthesis | 1 | 1989 | 98 | 0.010 |
Why?
|
| Heparin | 1 | 1989 | 185 | 0.000 |
Why?
|
| Ultrafiltration | 1 | 1987 | 13 | 0.000 |
Why?
|
| Hemofiltration | 1 | 1987 | 9 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1987 | 155 | 0.000 |
Why?
|
| Solvents | 1 | 1987 | 96 | 0.000 |
Why?
|
| Mitral Valve | 1 | 1989 | 262 | 0.000 |
Why?
|
| Heart Rate | 1 | 1989 | 498 | 0.000 |
Why?
|
| Sex Factors | 1 | 1990 | 1073 | 0.000 |
Why?
|
| Prevalence | 1 | 1990 | 1247 | 0.000 |
Why?
|
| Mice | 1 | 1996 | 11828 | 0.000 |
Why?
|